“Lung Cancer Vaccines: Pipeline, Strategies and Clinical” Published by MarketPublishers.com07 Oct 2011 • by Natalie Aster
LONDON – Lung cancer is considered to be the most common cancer across the globe. In 2008 there were around 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers.
The needs of patients along with the high burden of lung cancer are key drivers for the development of new therapies. Though, there are improvements in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies building on the capabilities of existing approaches are strongly required.
At present, developments are being made in drug treatments for lung cancer, in chemotherapy, new drug combinations and targeted molecules. In particular, there are advancements in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.
New research report “Lung Cancer Vaccines: Pipeline, Strategies and Clinical” drawn up by Biopharm Reports gives a comprehensive and detailed overview of 42 candidate vaccines, directed at 24 antigens or antigen combinations, that are being assessed for the treatment of lung cancer. The review focuses on pipeline, disease-targeting strategies and clinical findings in the treatment of lung cancer. Studies evaluating lung cancer alongside other cancers are also provided. All in all, the research work discusses developmental and market-related perspectives in this rapidly developing field.
Title: Lung Cancer Vaccines: Pipeline, Strategies and Clinical
Published: October, 2011
Price: US$ 1,520.00
CHAPTER 1 BACKGROUND
1 Lung Cancer
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
CHAPTER 2 APPROVED AND LATE-STAGE VACCINES
2.3 (One vaccine, Approved)
2.4 – 2.6 (Three vaccines, Phase 3)
2.7 (One vaccine, Phase 2/3)
CHAPTER 3 EARLY-STAGE VACCINES
3.3 – 3.12 (Ten vaccines, Phase 2)
3.13 – 3.22 (Ten vaccines, Phase 1/2)
3.23 – 3.37 (Fifteen vaccines, Phase 1)
3.38 – 3.39 (Two Vaccines, Preclinical)
CHAPTER 4 OTHER CANDIDATE THERAPIES
To order the report or ask for free sample pages, please contact email@example.com
The Market Publishers, Ltd.
Tel: +44 208 144 6009
Fax: +44 207 900 3970